The Creeping Pearl Index: Distinguishing Between Clinical Trial Efficacy and Actual-Use Effectiveness

The Creeping Pearl Index: Distinguishing Between Clinical Trial Efficacy and Actual-Use Effectiveness

The Creeping Pearl Index: Distinguishing Between Clinical Trial Efficacy and Actual-Use Effectiveness
RestartResume
Reversible contraception is widely used by virtually all reproductive aged women at some point in their lives, yet many patients and clinicians are...

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    Reversible contraception is widely used by virtually all reproductive aged women at some point in their lives, yet many patients and clinicians are unaware of how effective their chosen methods actually are and how efficacy is determined in both clinical trials and the real world. 

    This article will discuss various methods of reversible combined hormonal contraception (CHC), historical trends in contraceptive clinical trial design, the impact of obesity on efficacy, FDA guidance for trial conduct, perfect and actual use data, and shared decision-making around contraceptive choice.  Of particular note is the information surrounding “the Creeping Pearl Index.”

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Faculty:

    David Portman, MD
    Adjunct Instructor Obstetrics and Gynecology
    Ohio State University
    CEO and Chief Medical Officer
    Sermonix Pharmaceuticals
    Columbus, OH 

    Research Support: Agile Therapeutics
    Consulting Fees: Agile Therapeutics, Evofem Biosciences, Sebela Pharmaceuticals
    Salary/Stocks: Sermonix Pharmaceuticals

    Reviewers/Content Planners/Authors:

    • Sean T. Barrett has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Elizabeth Lurwick has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • Anita Nelson, MD, FACOG receives consulting fees from Agile Therapeutics, AMAG, American Regent, Bayer HealthCare, Merck, Sebela Pharmaceuticals, and TherapeuticsMD; serves in the commercial interest speakers bureaus for American Regent, Bayer HealthCare, Merck, and TherapeuticsMD; and does contracted research for Agile Therapeutics, Evofem, Merck, Mithra, and Sebela Pharmaceuticals.
    • Robert Schneider, MSW has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Explain the advantages and drawbacks of contraceptive patches and non-LARC methods.
    • Discuss the scientific data underlying the “Creeping Pearl Index” demonstrated in contemporary clinical trials of contraception.
  • Target Audience

    This activity is designed to meet the educational needs of obstetricians/gynecologists, nurse practitioners, physician assistants, nurses, certified nurse midwives, and primary care physicians with a focus on women’s health.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Omnia Education is the leading provider of education for women’s health professionals. Our activities are recognized nationwide for providing credible, relevant, and practical information on issues impacting the female patient. Additionally, our unique focus has transformed the CME learning environment, and our ability to help learners recognize and overcome barriers to optimal performance and optimal patient outcomes has positioned us as a leader in women’s health education.

  • Commercial Support

    This activity is supported by an independent educational grant from Agile Therapeutics. 

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

Facebook Comments

Register

We’re glad to see you’re enjoying Omnia Education…
but how about a more personalized experience?

Register for free